Background: This study assessed the effect of tirzepatide (TZP) on the 10-year risk of developing type 2 diabetes (T2D) in people with overweight or obesity with and without prediabetes.

Methods: The Cardiometabolic Disease Staging model was applied to the SURMOUNT-1 trial to derive T2D risk scores at baseline, 24, and 72 weeks. Mean change from baseline to week 72 was derived for participants with and without prediabetes at baseline.

Results: Age, sex, BMI, and other cardiometabolic factors were significantly different between participants with (n=987) and without prediabetes (n=1552). Mean baseline 10-year diabetes risk scores of participants with and without prediabetes were 29-32% and 19-20%, respectively, and did not differ by treatment group. Mean absolute reductions from baseline in the risk score at week 72 for TZP 5/10/15 mg were greater in participants with prediabetes (16-20%) vs those without prediabetes (10-11%), and both were greater than PBO. Mean change in 10-year risk vs PBO in the TZP 5/10/15 mg groups was -13%, -17%, and -18% respectively in those with prediabetes and -11%, -12%, and -12% in those without; the reduction was greater in participants with prediabetes (interaction p<0.001). Conclusion: TZP significantly reduced the predicted risk of developing T2D compared to PBO regardless of prediabetes status. Risk reduction was greater in participants with prediabetes.

graphic
View largeDownload slide
Disclosure

E. R. Hankosky: Employee; Eli Lilly and Company, Other Relationship; Eli Lilly and Company. H. Wang: None. L. M. Neff: Employee; Eli Lilly and Company, Research Support; Aegerion Pharmaceuticals, Stock/Shareholder; Eli Lilly and Company. H. Kan: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. F. Wang: None. N. Ahmad: Employee; Eli Lilly and Company. A. Stefanski: Employee; Eli Lilly and Company. W. Garvey: Advisory Panel; Boehringer-Ingelheim, Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Alnylam Pharmaceuticals, Inc., Fractyl Health, Inc., Inogen, Research Support; Novo Nordisk, Eli Lilly and Company, Epitomee, Pfizer Inc., Neurovalens.

Funding

Eli Lilly and Company

© 2023 by the American Diabetes Association
2023
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.